Bone Marrow Cell Therapy Reduced Fracture Risk
A small study suggests an experimental cell treatment may help postmenopausal women strengthen bone density and prevent fractures.
Updated on Sept. 19, 2026 in Arthritis
Live Poll
Do you generally trust the results of early-stage medical trials before they undergo large-scale testing?
Scientists recently developed a bone marrow cell therapy that showed promise in a small-scale study of 10 women with advanced postmenopausal osteoporosis. Over a two-year period, patients who received the infusion saw a 94% decrease in fracture rates.
Why it matters
This therapy aims to direct the body's own repair cells to damaged tissue, potentially offering a new way to restore bone health. Because the current study was limited in size and lacked a control group, these preliminary findings require further investigation before clinical adoption.
In a preliminary study of 10 women with advanced postmenopausal osteoporosis, researchers observed a 94% decrease in fracture rates over two years. Biopsies conducted four months post-therapy revealed a twofold increase in bone area, though findings remain preliminary due to the small sample size.
The details
The treatment involves isolating mesenchymal stromal cells from a patient's own bone marrow and tagging them with a structure called HCELL. This tag allows the cells to bind to E-selectin on blood vessels within the bone marrow, enabling them to attach to and penetrate damaged bone tissue. Once there, the cells promote regeneration, evidenced by bone formation markers that remained elevated for more than six months after infusion.
Timeline
4 months post-therapy: Biopsies showed nearly a twofold increase in bone area.
6 months post-therapy: Bone formation markers remained elevated.
2 years post-therapy: Fracture rates decreased by 94% and bone density increased.
6 years total: Follow-up period for the observed patients.
Health Landscape
This research contributes to the growing field of mesenchymal stromal cell therapies for orthopedic regeneration. It marks a potential departure from standard osteoporosis treatments that prioritize slowing bone loss toward an approach focused on active tissue repair.
This experimental therapy is in the early stages of research and is not currently a standard clinical option for patients. Discuss your current osteoporosis management plan and any new research developments with your physician to ensure your treatment strategy aligns with established clinical guidelines.
The takeaway
While this cell therapy trial showed a significant reduction in fracture rates, the results are preliminary and require further study to confirm safety and effectiveness. Individuals managing osteoporosis should continue to follow their physician-directed care plans and stay informed about long-term research.
Further reading
You can find more background on managing bone health and related conditions in our Arthritis section.
Source note: This article includes information reported by BGNES: Breaking News, Latest News and Videos.
Live Poll
Do you generally trust the results of early-stage medical trials before they undergo large-scale testing?
